V/P scan in diagnosis and follow-up of pulmonary embolism in 15-25-year-old females in relation to hormonal contraception use

Chroustová, Daniela; Kubinyi, Jozef; Jansa, Pavel; Vepřeková, Lenka; Trnka, Jiří

doi:10.5603/nmr.2011.00017

Cited by 4 publications

(6 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Deep vein thrombosis (DVT) was reported in 60% and pulmonary embolism in 30% of contraceptive users aged from 18 -49 [3]. In 59% of survivors, a permanent post-embolic residual deficit of lung perfusion was found on imaging [10]. The highest risk of thrombosis is typical for the first year of contraceptive use.…”

Section: Discussionmentioning

confidence: 99%

Pulmonary embolism associated with oral contraceptive use – Case report

Witczak¹,

Mosiewicz²,

Prystupa³

2015

J Pre Clin Clin Res.

View full text Add to dashboard Cite

A 25-year-old female patient with a history of oral contraceptive use was admitted to hospital because of exertional dyspnoea, palpitations, chest discomfort and weakness. Since the clinical presentation was suggestive of some heart disease the patient underwent echocardiography which revealed indirect signs of acute pulmonary embolism. The diagnosis was confirmed with multisliced computed tomography of the pulmonary arteries. Blood test results raised suspicion of antithrombin III deficiency. Enoxaparin and warfarin were used as treatment regimen with good effect and the patient was discharged home without significant symptoms, signs, and with normal echocardiography.

show abstract

Section: Discussionmentioning

confidence: 99%

Pulmonary embolism associated with oral contraceptive use – Case report

Witczak¹,

Mosiewicz²,

Prystupa³

2015

J Pre Clin Clin Res.

View full text Add to dashboard Cite

show abstract

“…In a retrospective analysis of 86 women, ages 15 to 25 years undergoing ventilation/perfusion scintigraphy because of suspicion of pulmonary embolism, PE was detected in only 3 (10%) of the 29 patients not using COC, but in 42% of the 57 women using COC. 29 The risk of VTE should also be considered in hospitalized and postsurgical adolescents using any type of CHC, and pediatric facilities may be less aware of these risks. In women using COC, VTE risk does not return to normal until 8 to 12 weeks after cessation of COC, so it is not recommended to hold these medications before surgical procedures.…”

Section: Recognitionmentioning

confidence: 99%

Contraception-Related Venous Thromboembolism in Adolescents

O’Brien

2013

Semin Thromb Hemost

View full text Add to dashboard Cite

Venous thromboembolism (VTE) is a rare but serious complication of combined hormonal contraception. While the absolute risk of VTE is low in adolescents, thrombotic events in contraception users younger than the age of 20 years account for 5 to 10% of total contraception-related VTE events in population studies, because of the high frequency of contraception use in adolescents. An increased risk of VTE exists not only with oral contraceptives, but also the contraceptive patch and vaginal ring. Most adolescents who experience contraception-related VTE have additional transient or inherited thrombotic risk factors at the time of VTE. Although the presence of inherited thrombophilia impacts the risk of contraception-related VTE, thrombophilia screening before contraception prescribing should be targeted only to high-risk populations. Pediatric institutions, caregivers, and young women need to be aware of the risk of VTE with estrogen-containing contraception, and maintain a high index of suspicion for this complication in women using these agents.

show abstract

“…VTE is rare event in young women and the risk associated with a new COC. But, many studies indicate that the well-known risk of VTE related to the use of COC needs to be considered as a cause of pulmonary embolism (PE) even among very young females [4]. So, prevention of these life-threatening conditions in patients without a family history of VTE consists of timely examination of their thrombotic profile and selection of appropriate medication.…”

Section: Introductionmentioning

confidence: 99%

Pulmonary embolism and deep vein thrombosis related to oral contraceptive use

Kim

2013

Obstet Gynecol Sci

View full text Add to dashboard Cite

Pulmonary embolism (PE) and deep vein thrombosis (DVT) is a serious medical problem causing considerable morbidity and mortality. Risk factors of thrombosis are surgery, trauma, pregnancy, tumor, oral contraceptive as well as genetic risk factors though genetic risk factors were found in about 5% to 10% of cases. Yasmin, a combined oral contraceptive containing ethinylestradiol 30 µg and drospirenon 3 mg was launched in the United Kingdom in 2002. We had experienced a patient, 24-year-old young woman with left inguinal pain on ambulation, and edema of left leg four months after taking Yasmin. We performed chest pulmonary angiography computed tomography (CT) and lower extremity venogram CT. She was diagnosed to PE in both lower lobes and DVT below the level of left external iliac vein, and treated by low molecular weight heparin and warfarin. We report this case with brief review of literatures.

show abstract

V/P scan in diagnosis and follow-up of pulmonary embolism in 15-25-year-old females in relation to hormonal contraception use

Cited by 4 publications

References 13 publications

Pulmonary embolism associated with oral contraceptive use – Case report

Pulmonary embolism associated with oral contraceptive use – Case report

Contraception-Related Venous Thromboembolism in Adolescents

Pulmonary embolism and deep vein thrombosis related to oral contraceptive use

Contact Info

Product

Resources

About